| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Heptanoate sodium does not have a defined pharmacological target as it is a surfactant and biochemical reagent. The compound is a sodium salt of heptanoic acid, a medium-chain fatty acid. It could be utilized as a surfactant, emulsifier, lubricant and preservative. The C(5) ketogenicity of heptanoate is much lower than the C(4) ketogenicity of octanoate, and it can inhibit the osteoporosis and gluconeogenesis of heptanoate.
|
|---|---|
| ln Vitro |
A biochemical reagent called heptenoate (sodium) can be utilized in life science research as an organic compound or biological material.
No specific in vitro pharmacological activity data are available for Heptanoate sodium as a drug candidate. In research settings, the compound is used as a surfactant and biochemical reagent. Its activity is assessed in terms of surfactant properties and metabolic effects rather than direct pharmacological activity. The compound is used in various research applications. |
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for Heptanoate sodium as a therapeutic agent. The compound is used as a surfactant and biochemical reagent. It is not administered to animals for pharmacological evaluation. Its applications are limited to in vitro biochemical research and industrial applications.
|
| Enzyme Assay |
For non-cellular assays, Heptanoate sodium is characterized by standard analytical techniques including HPLC, NMR, and elemental analysis to confirm identity and purity. Purity (nonaqueous titration): 97.0 to 101.0% (after drying). The compound has a molecular weight of 152.17 and molecular formula C₇H₁₃NaO₂. Storage: room temperature in a cool and dry place.
|
| Cell Assay |
For in vitro cell-based studies, Heptanoate sodium is not typically used as a direct test compound. It is used as a surfactant and biochemical reagent. If handled in a biological laboratory context, standard safety precautions should be taken. The compound is a solid at room temperature.
|
| Animal Protocol |
For in vivo animal studies, Heptanoate sodium is not typically administered as a test compound. It is used as a surfactant and biochemical reagent. If used in animal studies for specific research purposes, it would be administered via appropriate routes with suitable formulations. Standard animal welfare guidelines should be followed.
|
| ADME/Pharmacokinetics |
Heptanoate sodium has a molecular weight of 152.17 and molecular formula C₇H₁₃NaO₂. Purity: 97.0 to 101.0% (after drying). Storage: keep in a cool, dry place protected from light and moisture. The compound appears as a white to almost white powder to crystal.
|
| Toxicity/Toxicokinetics |
Heptanoate sodium is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD₅₀ values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
Heptanoate sodium (CAS 10051-45-3) is also known as sodium heptanoate, sodium enanthate, and enanthic acid sodium salt. It is an organic sodium salt compound extensively used as a surfactant, emulsifier, lubricant and preservative. No clinical trials or therapeutic approvals exist.
|
| Molecular Formula |
C7H13NAO2
|
|---|---|
| Molecular Weight |
152.17
|
| Exact Mass |
152.081
|
| CAS # |
10051-45-3
|
| Related CAS # |
Heptanoic acid;111-14-8
|
| PubChem CID |
23663651
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
222.6ºC at 760mmHg
|
| Flash Point |
99.2ºC
|
| Vapour Pressure |
0.0578mmHg at 25°C
|
| LogP |
0.706
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
10
|
| Complexity |
83.7
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCC(=O)[O-].[Na+]
|
| InChi Key |
NMTDPTPUELYEPL-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C7H14O2.Na/c1-2-3-4-5-6-7(8)9;/h2-6H2,1H3,(H,8,9);/q;+1/p-1
|
| Chemical Name |
sodium;heptanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (657.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5716 mL | 32.8580 mL | 65.7160 mL | |
| 5 mM | 1.3143 mL | 6.5716 mL | 13.1432 mL | |
| 10 mM | 0.6572 mL | 3.2858 mL | 6.5716 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
